Janssen Launching Phase 1 Trial Testing VE202 for Potential IBD Treatment

Janssen Launching Phase 1 Trial Testing VE202 for Potential IBD Treatment
Janssen Biotech will conduct a Phase 1 clinical trial in healthy volunteers to test VE202, an investigational oral treatment for inflammatory bowel disease (IBD), Vedanta Biosciences has announced. In 2015, Janssen bought the rights from Vedanta for VE202, an oral live biotherapeutic product (a treatment consisting of living microorganisms) that contains a curated mix of bacteria usually present in

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *